OBJECTIVE This pilot study investigates the dissolution profile, tolerability, and acceptability of an orally disintegrating olanzapine tablet in patients with schizophrenia. METHOD Eleven patients with schizophrenia stabilized on oral olanzapine (mean dosage 12.7 mg daily [SD5.2]) were given an orally disintegrating olanzapine tablet, rather than their usual tablet, daily for 7 days. At each...

Purpose: The aim of this research was to formulate and develop an orally disintegrating tablet (ODT) that incorporated a MEL/β-CD complex, using a quality by design (QbD) approach to enhance solubility and drug release. Methods: Multiple regression linear analysis was conducted to develop the kneading process and ODT formulation. Mixing time and amount of solvent were used as independent variab...

Orally disintegrating tablets are a solid dosage form compromising medicinal substances which disintegrate rapidly, generally within matter of seconds, when placed on the tongue. In this study, paracetamol orally was formulated and evaluated. Direct compression used to prepare 350 mg five formulations (F1- F5) by using single punch manual tableting machine. Pre-formulation studies were performe...

BACKGROUND Dexlansoprazole is a proton pump inhibitor (PPI) approved for use in dual delayed-release capsule and orally disintegrating tablet (ODT) formulations. AIM To assess effects of food, water, and route of administration on the bioavailability of dexlansoprazole 30-mg ODT. METHODS Two separate open-label, phase 1, single-dose crossover studies were conducted in healthy adults. In stu...

Rosuvastatin is a Dyslipidaemic Agents, which acts by inhibition of HMG-CoA reductase enzyme. Used in the treatment of hyperlipidemia. Therefore the present investigation was to design a formulation of orally disintegrating tablets of Rosuvastatin. Orally disintegrating tablets of Rosuvastatin were formulated by Superdisintegrant addition method by direct compression technique. All the fourteen...